Rates of race reporting and participation trends
lung cancer
LUNG CANCER
We analyzed the demographic data from a total of 426 lung cancer phase III clinical trials. We could not identify the United States only studies as most studies had authorships from multiple institutions across various regions in the United States, Europe, and Asia in various combinations. Only 137 studies (32.2%) reported race as a demographic (Figure (A) Pie chart illustrating the percentage of studies analyzed that reported race as a patient characteristic. (B) Histogram reporting the percentage of studies (of the studies that reported multiple races) that reported participation rates of each race category. (C) Histogram showing percent of studies published during each 5‐year period that reported demographic data on participant race along with the exact number of studies that reported race over the total number of studies published during that time in our database (as reported in the parentheses).The White participants represented 82.55% (95% CI 80.39%–84.71%) of study participants (Table Mean rates of participation of each race across analyzed lung cancer phase III clinical trials.

Two sample 


One‐way ANOVA test (among remaining races)








Abbreviation: ANOVA, analysis of variance.(A) Box plots illustrating the percentage of participants of each race in all the studies analyzed that reported race. (B) A scatter plot with a Pearson correlation coefficient of When looking at how participation rates changed with time, we found that the rate of White participants decreased at a rate of 0.51% per year (